Skip to main content
Fig. 2 | BMC Systems Biology

Fig. 2

From: Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model

Fig. 2

Parameters in the WB-PBPK model for irinotecan and the metabolites. Parameters are shown in the WB-PBPK model for irinotecan and the metabolites. a The kinds of parameters other than the metabolites in liver are same among irinotecan and the metabolites. Indicated are the blood flow (Q), the volume (V), the tissue-plasma partition coefficient (Kp), renal clearance (CLr), biliary clearance to transit compartment (CLbile), absorption rate constant (ka), kinetic constant for the transit in bile compartments to small intestine (kbile), kinetic constants for the transit from small intestine to large intestine (kL.I.), kinetic constant for the transit from large intestine to feces (kfeces), hepatic artery (H.A.) and hepatic vein (H.V.). The metabolic pathway of irinotecan and the metabolites in liver are represented b. Indicated are metabolic clearance of CPT-11 by CES2 to form SN-38 (CLCES,1), metabolic clearance of NPC by CES2 to form SN-38 (CLCES,2), metabolic clearance of CPT-11 by CYP3A4 to form APC (CL3A4,1), metabolic clearance of CPT-11 by CYP3A4 to form NPC (CL3A4,2) and metabolic clearance of SN-38 by UGT to form SN-38G (CLUGT)

Back to article page

BMC Systems Biology

ISSN: 1752-0509

Contact us